Novo Nordisk CagriSema Misses Non-Inferiority vs Lilly Zepbound
Novo Nordisk stumbles again: CagriSema trails Lilly’s Zepbound in key trial Novo said its next-gen obesity drug CagriSema hit 23% weight loss at 84 weeks, but it failed to prove non-inferiority versus Lilly’s tirzepatide (Zepbound) at 25.5%. Novo stock dropped about 15–16% on the day across reports; several outlets also cited a steep 12-month decline. […]
Novo Nordisk CagriSema Misses Non-Inferiority vs Lilly Zepbound Read More »